Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NQO2 | P16083 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | PGK1 | P00558 | 3/20 | 0.37 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.37 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | PDE3B | Q13370 | 3/20 | 0.35 |
| ▸ | PDE3A | Q14432 | 3/20 | 0.35 |
| ▸ | SRC | P12931 | 2/20 | 0.35 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | FGFR2 | P21802 | 1/20 | 0.33 |
| ▸ | RPS6KB2 | Q9UBS0 | 1/20 | 0.33 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.33 |
| ▸ | ABL1 | P00519 | 1/20 | 0.33 |
| ▸ | EGFR | P00533 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21215041 | 0.76 | ALDH1A1 (0.47) | NQO2KDM4EPOLBALDH1A1SMN1; SMN2 | |
| SCHEMBL14922469 | 0.75 | NQO2 (0.46) | NQO2KDM4EPOLBPGK1PDGFRB | |
| SCHEMBL12826420 | 0.70 | PGK1 (0.46) | NQO2KDM4EPGK1PDGFRBPDGFRA | |
| Ammonia Solution, Strong SCHEMBL10431156 | 0.65 | PGK1 (0.42) | NQO2KDM4EPGK1ALDH1A1PDE10A | |
| SCHEMBL11536024 | 0.64 | NPC1 (0.57) | KDM4EPDGFRBPDGFRAALDH1A1SMN1; SMN2 | |
| SCHEMBL29029328 | 0.64 | NQO2 (0.62) | NQO2KDM4EPOLBPGK1PDGFRB | |
| SCHEMBL348140 | 0.64 | PDGFRB (0.59) | NQO2KDM4EPGK1PDGFRBPDGFRA | |
| SCHEMBL9769066 | 0.63 | PGK1 (0.40) | NQO2KDM4EPGK1ALDH1A1 | |
| SCHEMBL10431155 | 0.63 | PGK1 (0.40) | NQO2KDM4EPGK1ALDH1A1 | |
| SCHEMBL1276533 | 0.63 | CYP3A4 (0.59) | NQO2KDM4EALDH1A1CYP3A4MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9610317-B2 | 4-amino-4-oxobutanoyl peptides as inhibitors of viral replication | ACHILLION PHARMACEUTICALS, INC. (US) | 2017-04-04 | — | — | US | disclosed |
| US-20160082069-A1 | 4-AMINO-4-OXOBUTANOYL PEPTIDES AS INHIBITORS OF VIRAL REPLICATION | ACHILLION PHARMACEUTICALS, INC. | 2016-03-24 | — | — | US | disclosed |
| US-9233136-B2 | 4-amino-4-oxobutanoyl peptides as inhibitors of viral replication | ACHILLION PHARMACEUTICALS, INC. (US) | 2016-01-12 | — | — | US | disclosed |
| US-20140328796-A1 | 4-AMINO-4-OXOBUTANOYL PEPTIDES AS INHIBITORS OF VIRAL REPLICATION | ACHILLION PHARMACEUTICALS, INC. | 2014-11-06 | — | — | US | disclosed |
| US-8785378-B2 | Macrocyclic peptides as inhibitors of viral replication | ACHILLION PHARMACEUTICALS, INC. (US) | 2014-07-22 | — | — | US | disclosed |
| US-8435984-B2 | Tertiary amine substituted peptides useful as inhibitors of HCV replication | ACHILLION PHARMACEUTICALS, INC. (US) | 2013-05-07 | — | — | US | disclosed |
| US-8163693-B2 | Urea-containing peptides as inhibitors of viral replication | ACHILLION PHARMACEUTICALS, INC. (US) | 2012-04-24 | — | — | US | disclosed |
| US-8163693-B2 | Urea-containing peptides as inhibitors of viral replication | ACHILLION PHARMACEUTICALS, INC. (US) | 2012-04-24 | — | — | US | disclosed |
| US-20110070168-A1 | MACROCYCLIC PEPTIDES AS INHIBITORS OF VIRAL REPLICATION | ACHILLION PHARMACEUTICALS, INC. (US) | 2011-03-24 | — | — | US | disclosed |
| US-7906619-B2 | 4-amino-4-oxobutanoyl peptides as inhibitors of viral replication | ACHILLION PHARMACEUTICALS, INC. (US) | 2011-03-15 | — | — | US | disclosed |
| US-20100292219-A1 | TERTIARY AMINE SUBSTITUTED PEPTIDES USEFUL AS INHIBITORS OF HCV REPLICATION | ACHILLION PHARMACEUTICALS, INC. (US) | 2010-11-18 | — | — | US | disclosed |
| US-20090082261-A1 | UREA-CONTAINING PEPTIDES AS INHIBITORS OF VIRAL REPLICATION | ACHILLION PHARMACEUTICALS, INC. (US) | 2009-03-26 | — | — | US | disclosed |
| US-20090082261-A1 | UREA-CONTAINING PEPTIDES AS INHIBITORS OF VIRAL REPLICATION | ACHILLION PHARMACEUTICALS, INC. (US) | 2009-03-26 | — | — | US | disclosed |
| US-20090048297-A1 | 4-AMINO-4-OXOBUTANOYL PEPTIDES AS INHIBITORS OF VIRAL REPLICATION | ACHILLION PHARMACEUTICALS (US) | 2009-02-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110070168-A1 | MACROCYCLIC PEPTIDES AS INHIBITORS OF VIRAL REPLICATION | VIP, ZC3HAV1, ZC3HAV1L | NQO2 1787/4885KDM4E 2227/4885POLB 743/4885 |
| US-20100292219-A1 | TERTIARY AMINE SUBSTITUTED PEPTIDES USEFUL AS INHIBITORS OF HCV REPLICATION | RTF2, RFC5, EIF2AK2 | NQO2 222/4885KDM4E 2472/4885POLB 307/4885 |
| US-20090082261-A1 | UREA-CONTAINING PEPTIDES AS INHIBITORS OF VIRAL REPLICATION | VIP, SLC14A1, RPL35 | NQO2 1688/4885KDM4E 2272/4885POLB 1145/4885 |
| US-20160082069-A1 | 4-AMINO-4-OXOBUTANOYL PEPTIDES AS INHIBITORS OF VIRAL REPLICATION | ZC3HAV1, VIP, ZC3HAV1L | NQO2 2049/4885KDM4E 680/4885POLB 402/4885 |
| US-20140328796-A1 | 4-AMINO-4-OXOBUTANOYL PEPTIDES AS INHIBITORS OF VIRAL REPLICATION | VIP, ZC3HAV1, CCL5 | NQO2 1208/4885KDM4E 868/4885POLB 765/4885 |
| US-20090048297-A1 | 4-AMINO-4-OXOBUTANOYL PEPTIDES AS INHIBITORS OF VIRAL REPLICATION | VIP, ZC3HAV1, CCL5 | NQO2 1208/4885KDM4E 868/4885POLB 765/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.